(Q26795694)

Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent

PubMed

volume

41

0 references

issue

4

0 references

page(s)

272-81

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Pathogenic role of mast cells in the development of diabetic nephropathy: a study of patients at different stages of the disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NOX enzymes and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Soluble forms of RAGE in internal medicine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Oxidative stress, Nox isoforms and complications of diabetes--potential targets for novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Superoxide auto-augments superoxide formation and upregulates gp91(phox) expression in porcine pulmonary artery endothelial cells: inhibition by iloprost

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

RAGE (receptor for advanced glycation end products): a central player in the inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The effects of diphenyleneiodonium on mitochondrial reactions. Relation of binding of diphenylene[125I]iodonium to mitochondria to the extent of inhibition of oxygen uptake

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labelling of a component polypeptide of the oxidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Subcellular localization of Nox4 and regulation in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Diphenyleneiodonium inhibits NF-kappaB activation and iNOS expression induced by IL-1beta: involvement of reactive oxygen species

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NADPH oxidases in the kidney

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Advanced glycation end-products and the kidney

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The AGE/RAGE axis in diabetes-accelerated atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Role of Nox2 in diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Mechanisms of diabetic complications.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

1 reference

7 January 2021

NOX4 is a Janus-faced reactive oxygen species generating NADPH oxidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Apocynin, NADPH oxidase, and vascular cells: a complex matter

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

RAGE expression in human T cells: a link between environmental factors and adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Mechanisms of PEDF-mediated protection against reactive oxygen species damage in diabetic retinopathy and neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Novel pathways and therapies in experimental diabetic atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The role of AGEs in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Classical inhibitors of NOX NAD(P)H oxidases are not specific.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

The renin-angiotensin system and advanced glycation end-products in diabetic retinopathy: impacts and synergies

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

From form to function: the role of Nox4 in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Septic shock is associated with receptor for advanced glycation end products ligation of LPS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021

Human galectin-3 is a novel chemoattractant for monocytes and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.DIABET.2015.01.006

7 January 2021